Company presentation Dec 2016

Lymfactin® and CDNF: Aiming at breakthrough in unmet clinical needs
Disclaimer

• This presentation does not intend to provide a thorough and detailed view of Herantis Pharma Plc (‘Company’). The information provided in this presentation shall not be considered sufficient for making any investment decisions related to the Company. Anyone considering an investment in the Company shall read and consider carefully all information provided in the formal prospectus approved by Finland’s Financial Supervisory Authority (Finanssivalvonta).

• This presentation may include forward-looking statements, estimates, and calculations related e.g. to the Company and its markets. Such forward-looking statements, estimates, and calculations are based on expectations and assumptions of the Company, which may be inaccurate or untrue. They also involve known and unknown risks and other factors, which might cause any estimates made by the Company to materially deviate from those actualized, including the operations, financial situation, and achievements of the Company. The Company cannot be held liable for any such deviations or for any actions taken by any party based on this presentation. Known risks related to the future of the Company and its business have been described in the formal prospectus approved by Finland’s Financial Supervisory Authority (Finanssivalvonta).
Herantis Pharma Plc

• Public drug development company developing novel pharmaceutical products based on globally leading science

• Focus in regenerative medicine, developing novel compounds with breakthrough potential in indications with significant unmet clinical needs

• Herantis’ proprietary, patented clinical stage compounds are:
  – Lymfactin® gene therapy for secondary lymphedema
  – CDNF protein therapy for Parkinson’s Disease and other neurodegenerative diseases
  – Cis-UCA Eye Drops for Dry Eye

• Herantis’ shares are listed in Nasdaq First North Helsinki with ticker ‘HRTIS’
# Herantis development pipeline

<table>
<thead>
<tr>
<th>Drug candidate</th>
<th>Indication</th>
<th>Preclin</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lymfactin®</td>
<td>Secondary lymphedema</td>
<td>▲</td>
<td>▲</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CDNF neuroprotective factor</td>
<td>Parkinson’s disease*</td>
<td>▲</td>
<td>▲</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CDNF neuroprotective factor</td>
<td>Amyotrophic lateral sclerosis (ALS)</td>
<td>▲</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CDNF neuroprotective factor</td>
<td>Other neurodegenerative diseases</td>
<td></td>
<td></td>
<td>**</td>
<td></td>
</tr>
<tr>
<td>Cis-UCA Eye Drops</td>
<td>Dry Eye</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
</tr>
<tr>
<td>Cis-UCA Emulsion Cream</td>
<td>Atopic dermatitis</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
</tr>
</tbody>
</table>

*Phase 1 started by submissions of Clinical Trial Applications
**Promising unpublished preclinical data exist. Formal development program not started.
Lymfactin® for secondary lymphedema

*Lymfactin® is the world’s first clinical stage gene therapy aiming to repair the lymphatic system*

- Secondary lymphedema is a chronic progressing disease with no approved medicines
  - Lymphedema significantly impacts quality of life and is of growing awareness as significant unmet clinical need; in 2016, March 6th declared World Lymphedema Day

- Preclinical data suggest Lymfactin® can repair the cause of lymphedema
  - World’s first clinical stage gene therapy aiming to repair the lymphatic system
  - Potential also in primary lymphedema in combination with our patented CCBE1

- Phase 1 clinical study ongoing in patients with breast cancer associated lymphedema
  - Top-line results expected in 2017

- Market size estimated in € hundreds of millions
CDNF for Parkinson’s disease (PD)

Preclinical data suggest CDNF is the most promising disease-modifying treatment for PD

- Parkinson’s disease is a progressive neurodegenerative disease, which cannot be cured
  - Estimated seven million patients worldwide
  - Current market over $3 billion with treatments that only help motor symptoms of the disease
  - Disease modification and non-motor symptoms remain as huge unmet clinical needs

- Based on broad preclinical data CDNF is expected to address both motor and non-motor symptoms and slow disease progression
  - CDNF protects and restores dopaminergic neurons based on studies in several preclinical PD models (both rodents and primates)
  - Completed extensive toxicology program suggests benign safety profile

- The European Union has granted €6 million for our Phase 1-2 randomized, placebo-controlled clinical study in Parkinson’s disease
Herantis’ assets based on globally leading science in their fields

CDNF based on long term research by professor Mart Saarma
• Vice President of European Research Council (ERC)
• Numerous international science prizes including Karl Schlossmann Science Prize, Runeberg Medical Science Prize, Finnish Innovation Prize, Estonian State Prize for Science and Technology
• Among leading and most appreciated researchers in the world in the field of neurotrophic factors

Lymfactin® based on long term research by professor Kari Alitalo
• Over 500 scientific publications
• Numerous international science prizes including InBev-Baillet Latour International Health Prize, Louis Jeantet Prize for Medicine, Anders Jahre Prize, Dr. A.H. Heineken Prize
• Among leading and most appreciated researchers in the world in the field of vascular endothelial growth factors (VEGFs)
Thank you